Pharmaceutical reform and physician strikes in Korea: Separation of drug prescribing and dispensing

Social Science and Medicine

Volumn 57, Issue 3, 2003, Pages 529-538

  Kwon, Soonman ^a  

^a Seoul National University   (South Korea)

Author keywords

Korea; Pharmaceuticals; Physician strike; Separation of prescribing and dispensing

Indexed keywords

DISTRIBUTION SYSTEM; DRUG PRESCRIBING; PHARMACEUTICAL INDUSTRY; REFORM PROCESS;

ARTICLE; COMMERCIAL PHENOMENA; CONSUMER; DRUG CLASSIFICATION; DRUG INDUSTRY; DRUG MISUSE; DRUG QUALITY; DRUG USE; GOVERNMENT; HEALTH CARE; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH SERVICE; HUMAN; INCOME; KOREA; MEDICAL FEE; MEDICAL PRACTICE; OUTPATIENT; PHARMACIST; PRESCRIPTION; PROFIT; SOCIAL ASPECT; TRADE UNION; TRADITIONAL MEDICINE;

CONSUMER PARTICIPATION; DRUG INDUSTRY; DRUG UTILIZATION; FEES, MEDICAL; GOVERNMENT REGULATION; HEALTH CARE REFORM; HEALTH SERVICES MISUSE; HUMANS; KOREA; LEGISLATION, DRUG; PHARMACISTS; PHYSICIANS; POLICY MAKING; POLITICS; PRESCRIPTIONS, DRUG; SOCIOLOGY, MEDICAL; STRIKES, EMPLOYEE;

SOUTH KOREA;

EID: 0013496304     PISSN: 02779536     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0277-9536(02)00378-7     Document Type: Article

References (40)

1. Busse, R., & Horworth, C. (1996). Fixed budgets in the pharmaceutical sector in Germany: Effects on costs and quality. In F. Schwartz, H. Glennerster, & R. Saltman (Eds.), Fixing health budgets: Experience from Europe and North America (pp. 109-127). New York: Wiley.
2. Cho B. The politics of herbal drugs in Korea. Social Science & Medicine. 51(4):2000;505-509.
3. Chou, Y., Yip, W., Lee, C., Huang, N., Sun, Y., & Chang, H. (2001). Impact of separating drug prescribing and dispensing on provider behavior: Taiwan's experience Mimeo. Boston: Harvard School of Public Health.
4. Danzon P. Pharmaceutical price regulation: National policies versus global interests. 1997;AEI Press, Washington, DC.
5. Danzon P., Chao L.W. Cross-national price difference for pharmaceuticals. How large and why? Journal of Health Economics. 19(2):2000;159-195.
6. Davis P. Managing medicines: Public policy and therapeutic drugs. 1997;Open University Press, Philadelphia.
7. Delnoij D., Brenner G. Importing budget systems from other countries. What can we learn from the German drug budget and the British GP fundholding Health Policy. 52(3):2000;157-169.
8. Giuliani G., Selke G., Garattini L. The German experience in reference pricing. Health Policy. 44(1):1998;73-85.
9. Grabowski H., Vernon J. Brand loyalty, entry, and price competition in pharmaceuticals after the 1984 drug act. Journal of Law and Economics. 35(2):1992;331-350.
10. Grant, C., & Yuen, P. (1998). The Hong Kong health care system. Australian Studies in Health Service Administration No. 84. Kensington, NSW: University of New South Wales.
11. Grindle M., Thomas J. Public choices and policy change: The political economy of reform in developing countries. 1991;Johns Hopkins University Press, Baltimore.
12. Hellerstein J. The importance of the physician in the generic versus trade-name prescription decision. Rand Journal of Economics. 29(1):1998;108-136.
13. Kim, Y. (2000). Health and the pharmaceutical reform on the separation of prescribing and dispensing. The pharmaceutical reform symposium. Seoul: Korea Health Industry Development Institute (in Korean).
14. Kingdon J. Agenda, alternatives, and public policies. 2nd ed. 1995;Harper Collins, New York.
15. Korean Association of Pharmaceutical Manufacturers (1998). Pharmaceutical industry statistics. Seoul (in Korean).
16. Kwon, S. (2002a). Achieving health insurance for all: Lessons from the Republic of Korea. ESS (Extension of Social Security) Paper No. 1. Geneva: ILO (International Labor Office).
17. Kwon, S. (2002b). Payment system reform for health care providers in Korea. Health Policy and Planning, forthcoming.
18. Kwon, S. (2002c). Health care financing reform and the new single payer system in Korea: Social solidarity or efficiency? International Social Security Review, forthcoming.
19. Kwon, S. (2002d). Quality of life associated with health and health care in Korea. Social Indicators Research, forthcoming.
20. Lopez-Casasnovas G., Puig-Junoy J. Review of the literature on reference pricing. Health Policy. 54(2):2000;87-123.
21. Lundin D. Moral hazard in physician prescription behavior. Journal of Health Economics. 19(3):2000;639-662.
22. Ministry of Health and Welfare (MOHW) (2000/2001). Internal report. Seoul (in Korean).
23. Moore W., Newman R. Drug formulary restrictions as a cost-containment policy in Medicaid programs. Journal of Law and Economics. 36(1):1993;71-98.
24. Mossialos E., Abel-Smith B. Cost containment in the pharmaceutical sector in the European Union member states. 1996;London School of Economics, London.
25. National Committee on Health Care Reform (NCHCR) (1997). Reform proposals. Seoul (in Korean).
26. National Health Insurance Corporation (NHIC) (1997a). Trend in health care provision in health insurance. Seoul (in Korean).
27. National Health Insurance Corporation (NHIC) (1997b). Internal report. Seoul (in Korean).
28. OECD (Organization for Economic Cooperation and Development) (1996). Health data 95. Paris.
29. Park, S. (1990). Policy making in the separation of prescribing and dispensing. Master of Public Administration Thesis. Seoul: Seoul National University (in Korean).
30. Petersen, M. (1994). Congress in the 1990s: From iron triangles to policy networks. In J. Morone & G. Belkin (Eds.), The politics of health care reform: Lessons from the past, prospects for the future (pp. 103-147). Durham: Duke University Press.
31. Rathwell, T. (1998). Implementing health care reform: A review of current experience. In R. Saltman, J. Figueras, & C. Sakellarides (Eds.), Critical challenges for health care reform in Europe (pp. 365-384). Philadelphia: Open University Press.
32. Reich, M. (1995). The politics of health sector reform in developing countries: Three cases of pharmaceutical policy. In P. Berman (Ed.), Health sector reform in developing countries: Making health development sustainable (pp. 59-99). Boston: Harvard School of Public Health.
33. Rodwin M., Okamoto A. Physicians' conflicts of interest in Japan and the United States. Lessons for the United States Journal of Health Politics, Policy and Law. 25(2):2000;343-375.
34. Saltman R., Figueras J. European health care reform: Analysis of current strategies. 1997;WHO (World Health Organization), Geneva.
35. Scherer F. Pricing, profits, and technological progress in the pharmaceutical industry. Journal of Economic Perspectives. 7(3):1993;97-115.
36. US General Accounting Office (GAO) (1994). Prescription drugs: Spending controls in four European countries. Washington, DC.
37. Walt G. Health policy: An introduction to process and power. 1994;Zed Books, Atlantic Highlands, NJ.
38. Weissert C., Weissert W. Governing health: The politics of health policy. 2nd ed. 2002;Johns Hopkins University Press, Baltimore.
39. Wilsford D. Path dependency, or why history makes it difficult but not impossible to reform health care systems in a big way. Journal of Public Policy. 14(3):1994;251-283.
40. Wilsford D. States facing interests. Struggles over health care policy in advanced industrialized democracies Journal of Health Politics, Policy and Law. 20(3):1995;571-613.